Idenix Reports Advancement of HCV Development Pipeline

Idenix Pharmaceuticals, Inc.

today announced the advancement of its hepatitis C virus development pipeline. IDX719: NS5A Program Idenix announced today the initiation of a phase I clinical trial of the Company's NS5A inhibitor, IDX719. The first part of the study will evaluate safety, pharmacokinetics and food effect of IDX719 in 48 healthy volunteers. A subsequent part of the study will evaluate three days of IDX719 treatment in treatment-naïve genotype 1 HCV-infected patients and is expected to begin in the second quarter of 2012. Preclinical studies have shown that IDX719 has potent, pan-genotypic activity in vitro with the potential for once-daily dosing. IDX19368 and IDX19370: Nucleotide Prodrug Program Further, the Company has selected two additional nucleotide inhibitors, IDX19368 and IDX19370, as potential clinical candidates. The Company anticipates Investigational New Drug (

) filings in mid-2012.